Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator.
Roche agrees for Sanofi to be responsible for the OTC marketing and distribution of Tamiflu in the US market, as it works on approval for its Xofluza competitor product.
SGS has completed a Phase I clinical trial of a new influenza virus strain in healthy volunteers and has increased capacity at its Mississauga, Canada-based laboratory.
Vaxart says its tablet delivery platform has simplified vaccine production so significantly it may bring manufacturing currently contracted to Lonza back in-house.
An influenza vaccine produced in tobacco plants could make a big impact in the market if it reaches the market in the US in time for the 2018-19 flu season, says a market analyst.
Drug industry efforts to develop a Zika vaccine are accelerating but it will be at least 18 months until the first candidates are ready for trials according to the WHO.
The US CDC has recommended that doctors give people Tamiflu (oseltamivir) after detecting that this year's vaccines a less effective than in previous years.
Researchers claiming Tamiflu cuts flu symptom duration and hospitalisations analysed less than half as many studies as were included in the 2014 Cochrane Collaboration review.
Southern California-based CRO WCCT Global is collaborating with the National Institute of Allergy and Infectious Diseases (NIAID) on influenza research.
Novartis’ seasonal flu vaccine Fluad has been deemed safe by the Italian Medicines Agency (AIFA) after testing the two batches connected to over a dozen deaths.
The World Health Organisation says a meeting between drugmakers and high-level government representatives last week has yielded plans to fast-track scale-up of Ebola vaccines in the face of incomplete trials and leaked production problems.
Ebola vaccine developers can seek scientific guidance and approval through a rolling assessment system established by EMA to accelerate the process review.
A seasonal flu vaccine taken in the form of an oral solid dose has been found comparable to currently available jabs, according to data presented by developer Vaxart.
Regulations governing the production of vaccines in China have been praised by WHO director general Margaret Chan following an assessment of the CFDA's oversight of the sector conducted last October.
GSK is confident it can meet Flulaval production targets ahead of this winter’s flu season despite ongoing endotoxin contamination problems at a Canadian plant hit with US FDA warning letter.
New EU laws safeguarding national ownership of ‘genetic resources’ may delay production of seasonal influenza vaccines according to EFPIA, which wants stakeholders to discuss the issue.
Scientists developing vaccines for potentially deadly diseases like influenza, SARS and HIV struggle to find a CRO with the right capabilities according to contractor TNO Triskelion.
Roche has asked Tamiflu distributors to prioritize US regions hardest hit by flu as it works to address packaging delays expected to limit supplies of the oral suspension version of the antiviral for the rest of the month.
NanoViricides' nanotech drug delivery platform has the potential to eliminate viruses, the firm says as construction began on a manufacturing facility to support upcoming clinical trials.
Novartis, the J. Craig Venter Institute, Synthetic Genomics Vaccines and the US CDC are racing to develop a vaccine for the H7N9 influenza virus sweeping through China.
Marinomed Biotechnologies is set to take on the ‘common cold’ in China with a new patent for an anti-viral polymer technology that prevents rhinovirus infection.
Use of deoxycholate to chemically disrupt influenza viruses during vaccine manufacture could be linked to adverse reactions in children, a journal reports.
US contract manufacturing organisation (CMO) Catalent has reported that no employees were injured in the fire that occurred at its packaging facility in the UK last week.
Novartis will use technology from Synthetics Genomics Vaccines to speed up the development of influenza vaccines for seasonal and pandemic flu outbreaks.
Cell culture, LAIV vaccines and recombinant DNA technology should be supported by the US government as part of a long-term overhaul of pandemic response capabilities, according to PCAST.
Abbott Laboratories has confirmed it is considering the sale of the vaccines unit it gained with the €4.5bn ($6.2bn) acquisition of Solvay Pharmaceuticals in February.
